CLINICAL TRIALS PROFILE FOR TOVIAZ
✉ Email this page to a colleague
All Clinical Trials for toviaz
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00605319 ↗ | An Open Label Study to Measure Efficacy of Fesoterodine (Toviaz) Post Surgery for Benign Prostatic Hyperplasia | Completed | Pfizer | Phase 4 | 2010-01-01 | The subjects who have symptoms of overactive bladder (many trips to the bathroom, and urgency with or without the inability to hold your urine until you get to the toilet) are invited to participate in this research study. |
| NCT00605319 ↗ | An Open Label Study to Measure Efficacy of Fesoterodine (Toviaz) Post Surgery for Benign Prostatic Hyperplasia | Completed | Weill Medical College of Cornell University | Phase 4 | 2010-01-01 | The subjects who have symptoms of overactive bladder (many trips to the bathroom, and urgency with or without the inability to hold your urine until you get to the toilet) are invited to participate in this research study. |
| NCT00691093 ↗ | Study In Patients With Overactive Bladder Treated With Toviaz® After Failure Of Previous Therapy | Completed | Pfizer | 2008-07-01 | This is a observational study in patients treated with fesoterodine (Toviaz), who have failed on previous treatment for overactive bladder. It will collect epidemiological data and investigate the efficacy and tolerability of fesoterodine. | |
| NCT00713921 ↗ | Neuropathic Investigation and Anticholinergic Treatment of Bladder Dysfunction in Diabetes and Stroke Patients | Withdrawn | Pfizer | Early Phase 1 | 2009-09-15 | Develop and quantify methods for evaluating bladder dysfunction in diabetes and stroke |
| NCT00713921 ↗ | Neuropathic Investigation and Anticholinergic Treatment of Bladder Dysfunction in Diabetes and Stroke Patients | Withdrawn | Saint Thomas Health | Early Phase 1 | 2009-09-15 | Develop and quantify methods for evaluating bladder dysfunction in diabetes and stroke |
| NCT00713921 ↗ | Neuropathic Investigation and Anticholinergic Treatment of Bladder Dysfunction in Diabetes and Stroke Patients | Withdrawn | Saint Thomas Health Services | Early Phase 1 | 2009-09-15 | Develop and quantify methods for evaluating bladder dysfunction in diabetes and stroke |
| NCT00798434 ↗ | A Study to Compare the Effectiveness and Safety of Fesoterodine and Placebo in an Elderly Population of Patients Who go to the Toilet Very Frequently Due to Overactive Bladder. | Completed | Pfizer | Phase 4 | 2008-06-01 | The drug being studied, fesoterodine fumarate helps prevent the bladder neck opening at unwanted times and has been shown to help patients with overactive bladder syndrome pass urine less frequently than before treatment. It is postulated that this drug will also prove effective in elderly patients (aged > 65 years) and that the ability to change dose between 4 and 8mg will allow each patient to have an optimised treatment. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for toviaz
Condition Name
Clinical Trial Locations for toviaz
Trials by Country
Clinical Trial Progress for toviaz
Clinical Trial Phase
Clinical Trial Sponsors for toviaz
Sponsor Name
